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Abstract
Background: Dementia takes decades to develop, and effective prevention will likely require early intervention. Thus, it is
critical to identify biomarkers of preclinical disease, allowing targeting of high-risk subjects for preventive efforts. Since
telomeres shorten with age and oxidative stress, both of which are important contributors to the onset of dementia,
telomere length might be a valuable biomarker.
Methodology/Principal Findings: Among 62 participants of the Nurses’ Health Study, we conducted neurologic evaluations,
including patient and caregiver interviews, physical exam, neurologic exam, and neuropsychologic testing. We also conducted
magnetic resonance imaging (MRI) in a sample of 29 of these women. In these preliminary data, after adjustment for numerous
health and lifestyle factors, we found that truncated telomeres in peripheral blood leukocytes segregate with preclinical
dementia states, including mild cognitive impairment (MCI); the odds of MCI were 12-fold higher (odds ratio = 12.00, 95%
confidence interval 1.24–116.5) for those with shorter telomere length compared to longer telomere length. In addition,
decreasing telomere length was strongly related to decreasing hippocampal volume (p=0.038).
Conclusions: These preliminary data suggest that telomere length may be a possible early marker of dementia risk, and
merits further study in large, prospective investigations.
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Introduction
Dementia takes years, if not decades, to develop. It is becoming
increasingly clear that effective prevention will require early
intervention – that is, prior to the onset of significant neurode-
generation or detectable clinical symptoms. Thus, discovering
biomarkers that predict preclinical disease is critical to successful
research on lifestyle factors or pharmaceutical agents that can
decrease dementia risk [1]. In recent years, telomere length has
emerged as a potential marker for biological aging and age-related
diseases. Telomeres, repetitive DNA structures that protect the
ends of eukaryotic chromosomes, shorten with age. Although
neurons are post-mitotic, telomere shortening has been observed
in microglia, and regulation of microglial activation may play a
important role in the pathogenesis of Alzheimer disease (AD)[2].
Moreover, as a site of high metabolic activity, brain tissue is
particularly vulnerable to oxidative damage, and long-term
oxidative stress with aging is believed to be an initiating factor
in dementia development [3]; since evidence indicates that both
age and oxidative damage contribute to telomere shortening [4],
telomere length could be a risk marker for dementia in its capacity
as a powerful measure of systemic imbalances in oxidative stress
and antioxidant defenses. Thus, several lines of evidence indicate
that telomere length might be a promising means of evaluating
early risk of AD development.
We used the Nurses’ Health Study to conduct a pilot study to
begin to explore whether telomere length in peripheral blood
leukocytes (PBL) might be associated with dementia, especially the
early phases marked by mild cognitive impairment (MCI) and
hippocampal atrophy.
Methods
Nurses’ Health Study
The Nurses’ Health Study began in 1976, when 121,700
registered female nurses, aged 30 to 55 years, from eleven US
states, responded to a mailed questionnaire. To date, 90% follow-
up of the cohort has been maintained. For this pilot study, we
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conducted detailed neurologic evaluations among a sample of
participants living in the Boston area. This sample was selected
from the 525 Nurses’ Health Study subjects in the Boston area
who were aged 70 years or older, and who participated in
telephone dementia screening [5] from 2005–2006. Briefly,
eligible subjects for the neurologic evaluation were all women
whose screening indicated possible cognitive impairments, and a
random selection of those with no apparent impairments. Of the
eligible women, 75% participated in the neurologic exam, and
participation rates were similar in those whose screening did and
did not indicate impairments. Neurologic evaluation included
patient and caregiver interviews, physical exam, neurologic exam,
and administration of the Weintraub Activities of Daily Living
Scale, Blessed Dementia Scale, and Clinical Dementia Rating
Scale. All subjects provided written, informed consent.
Based on the neurologic evaluations, of the 62 women in the
study sample, we diagnosed 5 with Alzheimer’s disease (by
NINCDS/ADRDA and DSM-IV criteria) and 8 with MCI (by
Peterson criteria), and 49 who were cognitively intact [6,7]. We
also conducted magnetic resonance imaging (MRI) in a sample of
29 of these women (3 with dementia, 7 with MCI, 19 cognitively
intact). We used a 1.5 T Siemens Avanto MRI scanner (Siemens
Medical Systems, Iselin, NJ) with high-resolution T1-weighted
scans. MPRAGE images were used to estimate regional atrophy in
the hippocampus (TR=7.25 msec, echo time TE=3.0 msec, flip
angle = 7u; FOV=256 mm, matrix = 2566192, 1.33 mm sagitally
acquired slices, NEX=1). Total hippocampal volume was
calculated by summing the volumes of the right and left
hippocampus, dividing by the intracranial volume, and multiply-
ing by 1000.
As the time of the neurologic exam, we collected blood samples
from all 62 participants. To measure PBL telomere length, we
extracted genomic DNA from buffy coats using the QIAmp
(Qiagen, Chatsworth, CA) 96-spin blood protocol. Relative
average telomere length, expressed as the ratio of telomeres to
single genes (T/S ratio), was assessed by a modified version of the
real-time PCR-based telomere assay [8].
Statistical Analysis
To quantify the relation of PBL telomere length to odds of
dementia and MCI, we used logistic regression models to compute
the odds ratios (OR) and 95% confidence intervals (CI),
comparing women with shorter telomere length (defined as
relative T/S ratio below the median) versus longer telomere
length (relative T/S ratio above the median). We also used linear
regression models to estimate adjusted mean differences in
hippocampal volume associated with each unit increase in relative
T/S ratio. In the regression models, we considered the following
potential confounding factors: age (continuous years), educational
attainment (college degree, master/doctoral degree), cigarette
smoking (never or past, current), history of cardiovascular disease
(yes, no), high blood pressure (yes, no), high cholesterol (yes, no),
and type 2 diabetes (yes, no).
Results
As expected, women with MCI or dementia were slightly older
than controls, although the age distribution in this cohort was
relatively narrow, and had less education than controls (Table 1).
Blood pressure was somewhat lower in the cases than controls. On
average, mean telomere length was progressively shorter in those
with MCI or dementia than controls, as was mean hippocampal
volume.
After adjusting for age and educational attainment (Table 2), we
found that women with PBL telomere length below the median
had a statistically significant, higher odds of dementia or MCI
(OR=9.63, 95% CI 1.73–53.65). Second, we examined telomere
length in relation to pre-clinical disease only (Table 1); the odds of
MCI were 12-fold higher (OR=12.00, 95% CI 1.24–116.5) for
those with shorter telomere length compared to longer telomere
length. Further adjustment for a variety of health and lifestyle
factors did not appreciably change any of these results.
We also examined the relation of PBL telomere length to
hippocampal volume (data not shown in table). We excluded
women with dementia from these analyses, so that we could assess
telomere length as a possible marker for pre-clinical changes in
hippocampal volume. We found that decreasing telomere length
was strongly related to decreasing hippocampal volume; after
Table 1. Characteristics of Controls, Cases of Mild Cognitive Impairment (MCI), and Cases of Dementia
Controls (n=49) MCI cases (n =8) Dementia cases (n =5)
Mean age (SD), years 79.2 (2.2) 79.9 (1.3) 80.0 (1.4)
Master’s or doctorate degree (%) 8.5 0.0 0.0
Mean systolic blood pressure (SD), mmHg 136.6 (17.3) 136.3 (13.0) 132.0 (17.9)
Mean diastolic blood pressure (SD), mmHg 75.6 (9.4) 73.4 (9.5) 71.8 (12.1)
Mean telomere length (SD), measured as relative
telomere/single gene ratio
0.61 (0.14) 0.51 (0.08) 0.49 (0.09)
Mean right hippocampal volume (SD) 2.13 (0.40) 1.86 (0.35) 1.37 (0.68)
Mean left hippocampal volume (SD) 1.93 (0.36) 1.74 (0.24) 1.40 (0.42)
doi:10.1371/journal.pone.0001590.t001
Table 2. Odds of Dementia or Mild Cognitive Impairment
(MCI), According to Telomere Length
Odds Ratio* (95%
confidence interval) for
Dementia/MCI
Odds Ratio* (95%
confidence interval)
for MCI only
Shorter telomere
length vs. longer
telomere length{
9.63 (1.73–53.65) 12.00 (1.24–116.46)
*Odds ratios are adjusted for age and educational attainment.
{Telomere length measured as relative telomere to single gene ratio in
peripheral blood leukocytes. Shorter telomere length was defined as below the
median in the population of those without any dementia or mild cognitive
impairment.
doi:10.1371/journal.pone.0001590.t002
Telomeres and Dementia
PLoS ONE | www.plosone.org 2 February 2008 | Volume 3 | Issue 2 | e1590
adjusting for age and educational attainment, each unit decrease
in relative T/S ratio resulted in a 0.25 mL decrease in
hippocampal volume (p = 0.038). Adjustment for a variety of
health and lifestyle factors did not alter these findings.
Discussion
These preliminary data are the first to suggest that shorter PBL
telomere length is related to combined dementia/MCI diagnosis,
as well as to pre-clinical dementia risk, including both MCI and
decreased hippocampal volume. Observed relations were inde-
pendent of age, educational attainment, cigarette smoking, and
various vascular factors, suggesting that PBL telomere length may
be a specific marker of dementia.
In particular, our findings for a relation between telomere
length and hippocampal volume in those without dementia
indicate the possibility that telomere shortening may be a very
early indicator of dementia risk. In understanding the magnitude
of association we observed between telomere length and
hippocampal volume, we compared our results to other studies
of hippocampal volume in older subjects. For example, the
Rotterdam study reported that the apolipoproteinE e4 allele was
related to a 0.21 mL decrease in hippocampal volume [9], while
we found that each single 0.1 unit change in the telomere to single
gene ratio was related to a 0.25 mL decrease in hippocampal
volume (ie, a 0.2 unit change is related to a 0.50 mL decrease; a
0.3 unit change is related to a 0.75 mL decrease, etc).
Limitations of these results should be considered. First, this was
a cross-sectional study, thus it cannot be determined whether
telomere length predicts dementia or whether dementia leads to
telomere shortening. However, in the context of a disease marker,
establishing such temporal associations may not be critical.
Moreover, our findings were consistent across a variety of disease
states, from dementia to MCI to reduced hippocampal volume,
suggesting that telomere shortening is an early sign of disease,
rather than a later effect of disease onset. Second, the study sample
was very small, and, although findings were statistically significant,
the confidence intervals were large, indicating that the data were
compatible with a wide range of associations. Thus, these should
only be considered as preliminary findings, and interpreted with
caution. Nonetheless, it is reassuring that we observed robust
associations between telomere length and multiple cognitive
outcomes. In addition, the limited literature generally supports
our findings. In a small, prospective study of 195 stroke survivors,
telomere length in peripheral blood mononuclear cells (PBMC) at
baseline was significantly related to both risk of developing
dementia over two years (OR=0.1, 95% CI 0.0–0.8) and to
decline on the MMSE, with a mean decrease of 0.77 points on the
MMSE for each 1000 bp decrease in telomere length (p= 0.04)
[10]. Among 257 older Hispanic, Caucasian and African-
American individuals, in a nested case-control study, PBL
telomere length was shorter in those with AD than controls
(mean=0.46 vs 0.52, p,0.03, respectively) [11]. Finally, in a
cross-sectional study of PBL telomere length in 559 older subjects,
there was a significant relation between PBL telomere length and
verbal fluency (p = 0.02), although not other cognitive systems
[12].
Overall, these preliminary data and limited existing studies
indicate a possible role for PBL telomere length in identifying
older persons with high risk of dementia. As an easily-measured
and non-invasive biomarker, further research regarding these
relations in large, prospective studies is needed.
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